Skip to main content

DuPont de Nemours, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

DD$155.14+5.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Fair Value Measurements

NOTE 20 -FAIR VALUE MEASUREMENTS

Fair Value Measurements on a Recurring Basis

The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:

Basis of Fair Value Measurements on a Recurring Basis of Significant Other Observable Inputs (Level 2)September 30, 2025December 31, 2024
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1$265$314
Net investment hedge43137
Foreign currency contracts 31723
Total assets at fair value$325$474
Liabilities at fair value:
Interest rate swap agreements126206
Foreign currency contracts 31723
Total liabilities at fair value$143$229
  1. Time deposits included in "Cash and cash equivalents" in the interim Condensed Consolidated Balance Sheets are held at amortized cost, which approximates fair value. "Restricted cash and cash equivalents" and "Restricted cash and cash equivalents - noncurrent" in the interim Condensed Consolidated Balance Sheets of $1,867 million and $42 million at September 30, 2025 and December 31, 2024, respectively, are deposited in money market funds and represent Level 1 fair value measurement investments which are held at amortized cost.

  2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.

  3. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the interim Condensed Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts for foreign currency contracts were $9 million andzero respectively, for both assets and liabilities as of September 30, 2025. The offsetting counterparty and cash collateral netting amounts were $15 million andzero, respectively, for assets and liabilities as of December 31, 2024.

As part of the Donatelle Plastics Acquisition, the purchase agreement includes annual contingent earn-out payments based upon customer specific revenue generated through December 31, 2029, with total accumulated earn-out payments of up to $85 million. The contingent earn-out liability was established using a Monte Carlo simulation and the significant assumption used is the estimated likelihood the customer specific revenue is earned. The contingent earn-out liability estimate represents a recurring fair value measurement with significant unobservable inputs. The fair value of the contingent earn-out liability is sensitive to changes in the interest rates, discount rates and the timing of the future payments, which are based upon estimates of future achievement of the customer specific revenue. As of September 30, 2025, the Company recognized an adjustment of approximately $19 million related to reflect the latest developments in the future achievement of the customer specific revenue being earned. See Note 3 for additional information.

Basis of Fair Value Measurements on a Recurring Basis of Significant Unobservable Inputs (Level 3)September 30, 2025December 31, 2024
In millions
Liabilities at fair value:
Contingent earn-out liabilities$21$40
Total liabilities at fair value$21$40

2025 Fair Value Measurements on a Nonrecurring Basis

During the third quarter of 2025, in relation to the Aramids Divestiture meeting the criteria to be classified as held for sale, the Company recorded a valuation allowance against the Aramids Business assets held for sale. The impairment analysis was performed using Level 3 inputs within the fair value hierarchy. See Note 4 for further discussion.

During the first quarter of 2025, the Company recorded an impairment charge related to goodwill within the Aramids reporting unit presented within discontinued operations. The impairment analysis was performed using Level 3 inputs within the fair value hierarchy. See Note 12 for further discussion.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.